{"id":"NCT02672111","sponsor":"Braeburn Pharmaceuticals","briefTitle":"Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder","officialTitle":"An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-05","completion":"2017-05","firstPosted":"2016-02-03","resultsPosted":"2019-08-01","lastUpdate":"2020-05-15"},"enrollment":228,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Opioid Use Disorder"],"interventions":[{"type":"DRUG","name":"CAM2038 q1w or q4w exposure to SL BPN/NX","otherNames":["Buprenorphine injection"]},{"type":"DRUG","name":"CAM2038 q1w or q4w new to BPN treatment","otherNames":["Buprenorphine injection"]}],"arms":[{"label":"CAM2038 q1w or q4w exposure to SL BPN/NX","type":"EXPERIMENTAL"},{"label":"CAM2038 q1w or q4w new to BPN treatment","type":"EXPERIMENTAL"}],"summary":"Open-label multi-center, 48 week safety study, consistent with standard practice for long-term safety studies. This one year safety study will utilize CAM2038 q1w (once weekly) and q4w (once monthly) and will have 3 phases: Screening, Treatment, and Follow-up.","primaryOutcome":{"measure":"Subjects With Treatment-Emergent Adverse Events (TEAE) During the Treatment Period-Overall Safety Population","timeFrame":"12 months- 48 week","effectByArm":[{"arm":"CAM2038 q1w or q4w With Prior Exposure to SL BPN/NX","deltaMin":131,"sd":null},{"arm":"CAM2038 q1w or q4w New to BPN Treatment","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States","Australia","Denmark","Germany","Hungary","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["31013390"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":190},"commonTop":["Injection site Pain","Injection SIte Swelling","Injection site erythema","Headache","Nasopharyngitis"]}}